Trump-era tariffs are noted to offer potential upside, impacting AI stocks and international expansion involving Acadia Pharmaceuticals and Europe.

The entities involved

• Donald Trump →

  American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)

  • Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
  • The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
• Europe →

  terrestrial continent located in north-western Eurasia

  • The European Commission aims to strengthen homegrown AI capabilities while global advanced models face usage restrictions.Mon 17:49
  • The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
• Acadia Pharmaceuticals →

  Pharmaceutical company, which developed Nuplazid, based in San Diego, California.

  Nothing else this week.

Related events

• Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.Jun 7
• Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.Jun 7
• The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.Jun 8
• AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.Jun 7
• AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.Jun 8